WCN26-6555 Predictive Factors for Glucocorticoid-Free Remission in Lupus Nephritis

Read full text Summarise with VIRAT
Authors: Ryota Sakai, Taiji Kosaka, Takumi Aoki, Yuri Sasaki, Shoichi Yoshinaga, Akiko Shibata, Takahiko Kurasawa, Koichi Amano, Hironari Hanaoka
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Glucocorticoids (GCs) are essential for induction therapy in lupus nephritis (LN), but they also contribute to long-term organ damage, metabolic complications, infections, and a reduced quality of life. The KDIGO 2024 guideline recommends tapering GCs to the lowest possible dose and considering discontinuation after ≥12 months of complete renal remission, reflecting a growing consensus toward GC withdrawal once remission is stable.

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106269–106269
Publication date
25 March 2026
Language
EN